United Nations Climate Change
Our aim is to help our clients understand the potential opportunities and challenges that COP25 may have on their business.
Case: AstraZeneca Canada Inc. v. Apotex Inc. (SCC file no. 36654)
Drug: NEXIUM® (esomeprazole)
Nature of case: Leave to Appeal of a judgment on invalidity of Canadian Patent No. 2,139,653 (‘653 Patent)
Successful party: AstraZeneca Canada Inc.
Date of decision: March 10, 2016
On March 10, 2016, the Supreme Court of Canada (SCC) granted AstraZeneca Canada Inc. (AstraZeneca) leave to appeal an order of the Federal Court of Appeal (FCA) affirming the Trial Judge’s finding that the ‘653 Patent is invalid for lack of utility (FCA Decision).
The FCA Decision contains an extensive discussion on the applicable standard for patent utility in Canada, including the "promise" doctrine. This is an opportunity for the SCC to provide guidance on an issue that has been the subject of much debate over recent years.
Apotex Inc. (Apotex) sought to impeach the ‘653 Patent on the basis of lack of utility, anticipation and obviousness. Justice Rennie held that the promised utility of the ‘653 Patent (compounds provide improved pharmacokinetic and metabolic properties with an improved therapeutic profile) was not demonstrated nor soundly predicted at the Canadian filing date. Apotex’s allegations of obviousness and anticipation were dismissed.
AstraZeneca appealed Justice Rennie’s decision on the following grounds: (a) he failed to consider the patent’s promised utility on a claim by claim basis; (b) he failed to construe the utility of the claims in a manner consistent with the inventive concept and; (c) he failed to apply a purposive construction to the promise of utility. The Federal Court of Appeal determined that the trial judge properly construed the “promise” of the patent by considering the patent as a whole through the eyes of the skilled reader, and properly considered the difference between “goals” and “promises”. The appeal was dismissed.
The Supreme Court of Canada Case Summary may be found at:
Our summary of the Federal Court of Appeal decision may be found here.
The Federal Court decision may be found at:
IMO 2020 is almost upon us. Readers are well aware of the impending switch to 0.5 percent fuel mandated by Annex VI of MARPOL which will cause an anticipated drop in HSFO demand, the potential hazards of new untested LSFO blends, the concerns around scrubber operations, the debate over open loop versus closed loop, and the myriad of other risks associated with the impending regulatory change.